These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 24307261)

  • 1. Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis.
    Osborne MT; Hulten EA; Singh A; Waller AH; Bittencourt MS; Stewart GC; Hainer J; Murthy VL; Skali H; Dorbala S; Di Carli MF; Blankstein R
    J Nucl Cardiol; 2014 Feb; 21(1):166-74. PubMed ID: 24307261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of serial quantitative evaluation of
    Muser D; Santangeli P; Castro SA; Liang JJ; Enriquez A; Werner TJ; Nucifora G; Magnani S; Hayashi T; Zado ES; Garcia FC; Callans DJ; Dixit S; Desjardins B; Marchlinski FE; Alavi A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1394-1404. PubMed ID: 29610956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis.
    Shelke AB; Aurangabadkar HU; Bradfield JS; Ali Z; Kumar KS; Narasimhan C
    Int J Cardiol; 2017 Feb; 228():717-722. PubMed ID: 27886616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.
    Blankstein R; Osborne M; Naya M; Waller A; Kim CK; Murthy VL; Kazemian P; Kwong RY; Tokuda M; Skali H; Padera R; Hainer J; Stevenson WG; Dorbala S; Di Carli MF
    J Am Coll Cardiol; 2014 Feb; 63(4):329-36. PubMed ID: 24140661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of serial
    Okafor J; Khattar R; Kouranos V; Ohri S; Diana D; Ebeke E; Azzu A; Ahmed R; Wells A; Baksi AJ; Sharma R; Wechalekar K
    J Nucl Cardiol; 2024 May; 35():101842. PubMed ID: 38479574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by ¹⁸F- fluorodoexyglucose positron emission tomography?
    Mc Ardle BA; Birnie DH; Klein R; de Kemp RA; Leung E; Renaud J; DaSilva J; Wells GA; Beanlands RS; Nery PB
    Circ Cardiovasc Imaging; 2013 Sep; 6(5):617-26. PubMed ID: 23884290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis.
    Dweck MR; Abgral R; Trivieri MG; Robson PM; Karakatsanis N; Mani V; Palmisano A; Miller MA; Lala A; Chang HL; Sanz J; Contreras J; Narula J; Fuster V; Padilla M; Fayad ZA; Kovacic JC
    JACC Cardiovasc Imaging; 2018 Jan; 11(1):94-107. PubMed ID: 28624396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.
    Okumura W; Iwasaki T; Toyama T; Iso T; Arai M; Oriuchi N; Endo K; Yokoyama T; Suzuki T; Kurabayashi M
    J Nucl Med; 2004 Dec; 45(12):1989-98. PubMed ID: 15585472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET in possible cardiac sarcoidosis: Right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events.
    Tuominen H; Haarala A; Tikkakoski A; Kähönen M; Nikus K; Sipilä K
    J Nucl Cardiol; 2021 Feb; 28(1):199-205. PubMed ID: 30815833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis.
    Tahara N; Tahara A; Nitta Y; Kodama N; Mizoguchi M; Kaida H; Baba K; Ishibashi M; Hayabuchi N; Narula J; Imaizumi T
    JACC Cardiovasc Imaging; 2010 Dec; 3(12):1219-28. PubMed ID: 21163450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of newly diagnosed sarcoidosis in patients with ventricular arrhythmias: a cardiac magnetic resonance and 18F-FDG cardiac PET study.
    Kebed KY; Carter SV; Flatley E; Ward RP; Moss JD; Appelbaum DE; Singh A; Lang RM; Tung R; Patel AR
    Int J Cardiovasc Imaging; 2021 Apr; 37(4):1361-1369. PubMed ID: 33225427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis.
    Lee PI; Cheng G; Alavi A
    J Nucl Cardiol; 2017 Feb; 24(1):19-28. PubMed ID: 27813028
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Omote K; Naya M; Koyanagawa K; Aikawa T; Manabe O; Nagai T; Kamiya K; Kato Y; Komoriyama H; Kuzume M; Tamaki N; Anzai T
    J Nucl Cardiol; 2020 Dec; 27(6):2135-2143. PubMed ID: 30610523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis.
    Flores RJ; Flaherty KR; Jin Z; Bokhari S
    J Nucl Cardiol; 2020 Dec; 27(6):2003-2010. PubMed ID: 30421379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis.
    Ahmadian A; Pawar S; Govender P; Berman J; Ruberg FL; Miller EJ
    J Nucl Cardiol; 2017 Apr; 24(2):413-424. PubMed ID: 27457527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of treatment response in cardiac sarcoidosis based on myocardial
    Frischknecht L; Schaab J; Schmauch E; Yalamanoglu A; Arnold DD; Schwaiger J; Gruner C; Buechel RR; Franzen DP; Kolios AGA; Nilsson J
    Front Immunol; 2023; 14():1286684. PubMed ID: 38077350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis.
    Yokoyama R; Miyagawa M; Okayama H; Inoue T; Miki H; Ogimoto A; Higaki J; Mochizuki T
    Int J Cardiol; 2015 Sep; 195():180-7. PubMed ID: 26043154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis.
    Matoh F; Satoh H; Shiraki K; Odagiri K; Saitoh T; Urushida T; Katoh H; Takehara Y; Sakahara H; Hayashi H
    J Cardiol; 2008 Jun; 51(3):179-88. PubMed ID: 18522793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol.
    Christopoulos G; Jouni H; Acharya GA; Blauwet LA; Kapa S; Bois J; Chareonthaitawee P; Rodriguez-Porcel MG
    J Nucl Cardiol; 2021 Apr; 28(2):661-671. PubMed ID: 31111450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
    Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
    J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.